For the first time we now have a randomised trial comparing active monitoring, surgery and radiation therapy for the management of localised prostate cancer and the investigators are to be congratulated on this highly anticipated landmark study - the Prostate testing for cancer and Treatment (ProtecT) trial. Comparing 545 patients randomised to active monitoring, 553 to radical prostatectomy, and 545 to radiotherapy, at a median follow-up of 10 years the study reports no significant difference in prostate-cancer specific or overall survival amongst the three groups. This article is protected by copyright. All rights reserved.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
BJU international. 2016 Jan 08 [Epub ahead of print]
Luke L Wang, Christopher J D Wallis, Niranjan Sathianathen, Nathan Lawrentschuk, Declan G Murphy, Robert Nam, Daniel Moon
Australian Urology Associates, Malvern, Victoria, Australia., Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada., Division of Cancer Surgery, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.